Weight Regain After Semaglutide Discontinuation in a Patient With Prediabetes
A 52-year-old woman with BMI 36.4 kg/m² (weight 98 kg, height 1.64 m) and prediabetes (A1c 6.2%) achieved 18% weight loss over 15 months on semaglutide 2.4 mg weekly plus lifestyle counseling. She now requests discontinuation because of cost and persistent nausea. Current weight is 80 kg, A1c 5.6%, blood pressure 118/74 mmHg. She has no history of diabetes, no cardiovascular disease, and takes no other medications. She reports that her appetite has returned to pre-treatment levels over the past month and that she has stopped attending the behavioral program. She asks what will happen if she simply stops the drug and whether there is a way to keep the weight off without it.
1. What is the expected trajectory of weight and glycemia after abrupt discontinuation, and what is the evidence-based recommendation for this patient?
Read the worked answer
Expected trajectory. In the STEP 1 extension, participants who stopped semaglutide 2.4 mg after 68 weeks regained roughly two-thirds of lost weight within the following year, and cardiometabolic improvements (A1c, blood pressure, lipids) reverted toward baseline. With an 18% loss, she is at high risk of regaining ~12% of body weight, which would move her BMI back toward the mid-30s and likely return A1c toward the prediabetic range.
Recommendation. Chronic obesity is a chronic disease; pharmacotherapy is generally long-term. Abrupt cessation without a maintenance plan is not evidence-based. Options:
- Address the reason for stopping - cost (patient assistance, alternative agent) and nausea (dose reduction to 1.7 mg, slower titration, dietary modification).
- If she still stops, intensify the behavioral program and arrange structured surveillance (weight, A1c every 3 months) with a pre-specified threshold for restarting pharmacotherapy.
- Consider an alternative or lower-cost agent if cost is the dominant driver, rather than no pharmacotherapy.
Key judgment. Do not promise that lifestyle alone will maintain an 18% loss; the data do not support that. Negotiate a maintenance plan with defined triggers for re-intervention.
2. She asks whether stopping the drug will 'cure' her prediabetes. How do you counsel her, and what monitoring do you arrange?
Read the worked answer
Counseling. The A1c improvement is largely drug- and weight-loss-dependent. On discontinuation, A1c typically drifts back up as weight is regained. Prediabetes is in remission, not cured. She should understand that the 5.6% A1c reflects active treatment plus weight loss, not a permanent change in biology.
Monitoring plan.
- A1c every 3 months for the first year after discontinuation, then annually if stable.
- Weight at each visit; define a regain threshold (e.g., >5% regain from nadir) that triggers reassessment.
- Blood pressure and lipids annually.
- Re-screen for type 2 diabetes if A1c reaches ≥6.5% on two occasions.
Framing. Emphasize that the goal is durable risk reduction, not a one-time number. If she regains weight and A1c rises, restarting therapy (or an alternative) is appropriate and not a failure.